<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32466216</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3719</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21103719</ELocationID><Abstract><AbstractText>Mitochondria play a central role in a plethora of processes related to the maintenance of cellular homeostasis and genomic integrity. They contribute to preserving the optimal functioning of cells and protecting them from potential DNA damage which could result in mutations and disease. However, perturbations of the system due to senescence or environmental factors induce alterations of the physiological balance and lead to the impairment of mitochondrial functions. After the description of the crucial roles of mitochondria for cell survival and activity, the core of this review focuses on the "mitochondrial switch" which occurs at the onset of neuronal degeneration. We dissect the pathways related to mitochondrial dysfunctions which are shared among the most frequent or disabling neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, Amyotrophic Lateral Sclerosis, and Spinal Muscular Atrophy. Can mitochondrial dysfunctions (affecting their morphology and activities) represent the early event eliciting the shift towards pathological neurobiological processes? Can mitochondria represent a common target against neurodegeneration? We also review here the drugs that target mitochondria in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stanga</LastName><ForeName>Serena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1454-0713</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10043 Orbassano (TO), Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neuroscience (INN), 10125 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caretto</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10043 Orbassano (TO), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boido</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1211-1552</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10043 Orbassano (TO), Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neuroscience (INN), 10125 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vercelli</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10043 Orbassano (TO), Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neuroscience (INN), 10125 Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>"Dipartimenti di Eccellenza 2018-2022" to Department of Neuroscience "Rita Levi Montalcini</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>RF 2017.2052</GrantID><Agency>Fondazione CRT</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="N">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001678" MajorTopicYN="N">Organelle Biogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cellular homeostasis</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">mitochondria biogenesis and dynamics</Keyword><Keyword MajorTopicYN="N">mitochondria targeting drugs</Keyword><Keyword MajorTopicYN="N">motor neuron diseases</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32466216</ArticleId><ArticleId IdType="pmc">PMC7279270</ArticleId><ArticleId IdType="doi">10.3390/ijms21103719</ArticleId><ArticleId IdType="pii">ijms21103719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu. Rev. Genet. 2005;39:359&#x2013;407. doi: 10.1146/annurev.genet.39.110304.095751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genet.39.110304.095751</ArticleId><ArticleId IdType="pmc">PMC2821041</ArticleId><ArticleId IdType="pubmed">16285865</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown T.A., Tkachuk A.N., Shtengel G., Kopek B.G., Bogenhagen D.F., Hess H.F., Clayton D.A. Superresolution fluorescence imaging of mitochondrial nucleoids reveals their spatial range, limits, and membrane interaction. Mol. Cell Biol. 2011;31:4994&#x2013;5010. doi: 10.1128/MCB.05694-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.05694-11</ArticleId><ArticleId IdType="pmc">PMC3233019</ArticleId><ArticleId IdType="pubmed">22006021</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele H.E., Horvath R., Lyon J.J., Chinnery P.F. Monitoring clinical progression with mitochondrial disease biomarkers. Brain. 2017;140:2530&#x2013;2540. doi: 10.1093/brain/awx168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx168</ArticleId><ArticleId IdType="pmc">PMC5841218</ArticleId><ArticleId IdType="pubmed">28969370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D.C. Mitochondrial fusion and fission in mammals. Annu. Rev. Cell Dev. Biol. 2006;22:79&#x2013;99. doi: 10.1146/annurev.cellbio.22.010305.104638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.22.010305.104638</ArticleId><ArticleId IdType="pubmed">16704336</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine. 5th ed. Volume xxxviii. Oxford University Press; Oxford, UK: 2015. 905p</Citation></Reference><Reference><Citation>Shadel G.S., Horvath T.L. Mitochondrial ROS signaling in organismal homeostasis. Cell. 2015;163:560&#x2013;569. doi: 10.1016/j.cell.2015.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.10.001</ArticleId><ArticleId IdType="pmc">PMC4634671</ArticleId><ArticleId IdType="pubmed">26496603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls D.G., Vesce S., Kirk L., Chalmers S. Interactions between mitochondrial bioenergetics and cytoplasmic calcium in cultured cerebellar granule cells. Cell Calcium. 2003;34:407&#x2013;424. doi: 10.1016/S0143-4160(03)00144-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0143-4160(03)00144-1</ArticleId><ArticleId IdType="pubmed">12909085</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomello M., Drago I., Pizzo P., Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ. 2007;14:1267&#x2013;1274. doi: 10.1038/sj.cdd.4402147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402147</ArticleId><ArticleId IdType="pubmed">17431419</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago I., De Stefani D., Rizzuto R., Pozzan T. Mitochondrial Ca2+ uptake contributes to buffering cytoplasmic Ca2+ peaks in cardiomyocytes. Proc. Natl. Acad. Sci. USA. 2012;109:12986&#x2013;12991. doi: 10.1073/pnas.1210718109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1210718109</ArticleId><ArticleId IdType="pmc">PMC3420165</ArticleId><ArticleId IdType="pubmed">22822213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922&#x2013;2933.</Citation><ArticleIdList><ArticleId IdType="pubmed">11711427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gahl R.F., Dwivedi P., Tjandra N. Bcl-2 proteins bid and bax form a network to permeabilize the mitochondria at the onset of apoptosis. Cell Death Dis. 2016;7:e2424. doi: 10.1038/cddis.2016.320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.320</ArticleId><ArticleId IdType="pmc">PMC5133987</ArticleId><ArticleId IdType="pubmed">27763642</ArticleId></ArticleIdList></Reference><Reference><Citation>Youle R.J., van der Bliek A.M. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062&#x2013;1065. doi: 10.1126/science.1219855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1219855</ArticleId><ArticleId IdType="pmc">PMC4762028</ArticleId><ArticleId IdType="pubmed">22936770</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456&#x2013;461. doi: 10.1126/science.1196371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1196371</ArticleId><ArticleId IdType="pmc">PMC3030664</ArticleId><ArticleId IdType="pubmed">21205641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemasters J.J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005;8:3&#x2013;5. doi: 10.1089/rej.2005.8.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2005.8.3</ArticleId><ArticleId IdType="pubmed">15798367</ArticleId></ArticleIdList></Reference><Reference><Citation>Palikaras K., Lionaki E., Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat. Cell Biol. 2018;20:1013&#x2013;1022. doi: 10.1038/s41556-018-0176-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0176-2</ArticleId><ArticleId IdType="pubmed">30154567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirienko N.V., Ausubel F.M., Ruvkun G. Mitophagy confers resistance to siderophore-mediated killing by Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA. 2015;112:1821&#x2013;1826. doi: 10.1073/pnas.1424954112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1424954112</ArticleId><ArticleId IdType="pmc">PMC4330731</ArticleId><ArticleId IdType="pubmed">25624506</ArticleId></ArticleIdList></Reference><Reference><Citation>West A.P., Khoury-Hanold W., Staron M., Tal M.C., Pineda C.M., Lang S.M., Bestwick M., Duguay B.A., Raimundo N., MacDuff D.A., et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553&#x2013;557. doi: 10.1038/nature14156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14156</ArticleId><ArticleId IdType="pmc">PMC4409480</ArticleId><ArticleId IdType="pubmed">25642965</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman G.S., Chinnery P.F., DiMauro S., Hirano M., Koga Y., McFarland R., Suomalainen A., Thorburn D.R., Zeviani M., Turnbull D.M. Mitochondrial diseases. Nat. Rev. Dis. Primers. 2016;2:16080. doi: 10.1038/nrdp.2016.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.80</ArticleId><ArticleId IdType="pubmed">27775730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.A., Wei Y., Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008;102:401&#x2013;414. doi: 10.1161/CIRCRESAHA.107.165472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.107.165472</ArticleId><ArticleId IdType="pmc">PMC2963150</ArticleId><ArticleId IdType="pubmed">18309108</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcelos I.P., Troxell R.M., Graves J.S. Mitochondrial dysfunction and multiple sclerosis. Biology. 2019;8:37. doi: 10.3390/biology8020037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology8020037</ArticleId><ArticleId IdType="pmc">PMC6627385</ArticleId><ArticleId IdType="pubmed">31083577</ArticleId></ArticleIdList></Reference><Reference><Citation>Porporato P.E., Filigheddu N., Pedro J.M.B., Kroemer G., Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265&#x2013;280. doi: 10.1038/cr.2017.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2017.155</ArticleId><ArticleId IdType="pmc">PMC5835768</ArticleId><ArticleId IdType="pubmed">29219147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Chen M., Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion. 2019;49:35&#x2013;45. doi: 10.1016/j.mito.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2019.07.003</ArticleId><ArticleId IdType="pubmed">31288090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla R., Manczak M., Yin X., Wang R., Reddy P.H. Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2018;27:30&#x2013;40. doi: 10.1093/hmg/ddx381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx381</ArticleId><ArticleId IdType="pmc">PMC5886218</ArticleId><ArticleId IdType="pubmed">29040533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X., Manczak M., Reddy P.H. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington&#x2019;s disease. Hum. Mol. Genet. 2016;25:1739&#x2013;1753. doi: 10.1093/hmg/ddw045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw045</ArticleId><ArticleId IdType="pmc">PMC4986329</ArticleId><ArticleId IdType="pubmed">26908605</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz T.L. Mitochondrial trafficking in neurons. Cold Spring Harb. Perspect. Biol. 2013;5:a011304. doi: 10.1101/cshperspect.a011304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a011304</ArticleId><ArticleId IdType="pmc">PMC3660831</ArticleId><ArticleId IdType="pubmed">23732472</ArticleId></ArticleIdList></Reference><Reference><Citation>Somlyai G., Jancs&#xf3; G., J&#xe1;kli G., Vass K., Barna B., Lakics V., Ga&#xe1;l T. Naturally occurring deuterium is essential for the normal growth rate of cells. FEBS Lett. 1993;317:1&#x2013;4. doi: 10.1016/0014-5793(93)81479-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)81479-J</ArticleId><ArticleId IdType="pubmed">8428617</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgun A. Biological effects of deuteration: ATP synthase as an example. Theor. Biol. Med. Model. 2007;4:9. doi: 10.1186/1742-4682-4-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4682-4-9</ArticleId><ArticleId IdType="pmc">PMC1808445</ArticleId><ArticleId IdType="pubmed">17316427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mladin C., Ciobica A., Lefter R., Popescu A., Bild W. Deuterium-depleted water has stimulating effects on long-term memory in rats. Neurosci. Lett. 2014;583:154&#x2013;158. doi: 10.1016/j.neulet.2014.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.09.037</ArticleId><ArticleId IdType="pubmed">25263786</ArticleId></ArticleIdList></Reference><Reference><Citation>Basov A., Fedulova L., Baryshev M., Dzhimak S. Deuterium-depleted water infulence on the isotope 2H/1H regulation in body and individual adaptation. Nutrients. 2019;11:1903. doi: 10.3390/nu11081903.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081903</ArticleId><ArticleId IdType="pmc">PMC6723318</ArticleId><ArticleId IdType="pubmed">31443167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu N., Lu B. Mechanisms and roles of mitophagy in neurodegenerative diseases. CNS Neurosci. Ther. 2019;25:859&#x2013;875. doi: 10.1111/cns.13140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13140</ArticleId><ArticleId IdType="pmc">PMC6566062</ArticleId><ArticleId IdType="pubmed">31050206</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S.V., Klionsky D.J. Delivery of proteins and organelles to the vacuole from the cytoplasm. Curr. Opin. Cell Biol. 1998;10:523&#x2013;529. doi: 10.1016/S0955-0674(98)80068-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0955-0674(98)80068-9</ArticleId><ArticleId IdType="pubmed">9719874</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezhnov A.V., Soutar M.P.M., Fedotova E.I., Frolova M.S., Plun-Favreau H., Zinchenko V.P., Abramov A.Y. Intracellular pH modulates autophagy and mitophagy. J. Biol. Chem. 2016;291:8701&#x2013;8708. doi: 10.1074/jbc.M115.691774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.691774</ArticleId><ArticleId IdType="pmc">PMC4861439</ArticleId><ArticleId IdType="pubmed">26893374</ArticleId></ArticleIdList></Reference><Reference><Citation>Missiroli S., Genovese I., Perrone M., Vezzani B., Vitto V.A.M., Giorgi C. The role of mitochondria in inflammation: From cancer to neurodegenerative disorders. J. Clin. Med. 2020;9:740. doi: 10.3390/jcm9030740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030740</ArticleId><ArticleId IdType="pmc">PMC7141240</ArticleId><ArticleId IdType="pubmed">32182899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew A., Lindsley T.A., Sheridan A., Bhoiwala D.L., Hushmendy S.F., Yager E.J., Ruggiero E.A., Crawford D.R. Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. J. Alzheimers Dis. 2012;30:617&#x2013;627. doi: 10.3233/JAD-2012-120145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120145</ArticleId><ArticleId IdType="pubmed">22460333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 2012;13:343&#x2013;351. doi: 10.1038/ni.2224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2224</ArticleId><ArticleId IdType="pubmed">22430787</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger? Science. 2010;327:296&#x2013;300. doi: 10.1126/science.1184003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1184003</ArticleId><ArticleId IdType="pubmed">20075245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221&#x2013;225. doi: 10.1038/nature09663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09663</ArticleId><ArticleId IdType="pubmed">21124315</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Won J.H., Hwang I., Hong S., Lee H.K., Yu J.W. Defective mitochondrial fission augments NLRP3 inflammasome activation. Sci. Rep. 2015;5:15489. doi: 10.1038/srep15489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15489</ArticleId><ArticleId IdType="pmc">PMC4614538</ArticleId><ArticleId IdType="pubmed">26489382</ArticleId></ArticleIdList></Reference><Reference><Citation>Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 2003;111:303&#x2013;312. doi: 10.1172/JCI200317741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200317741</ArticleId><ArticleId IdType="pmc">PMC151870</ArticleId><ArticleId IdType="pubmed">12569152</ArticleId></ArticleIdList></Reference><Reference><Citation>Trushina E., McMurray C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience. 2007;145:1233&#x2013;1248. doi: 10.1016/j.neuroscience.2006.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.10.056</ArticleId><ArticleId IdType="pubmed">17303344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117. doi: 10.1016/S0140-6736(05)67889-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67889-0</ArticleId><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W., De Strooper B. A cell biological perspective on Alzheimer&#x2019;s disease. Annu. Rev. Cell Dev. Biol. 2002;18:25&#x2013;51. doi: 10.1146/annurev.cellbio.18.020402.142302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.18.020402.142302</ArticleId><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K. Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer&#x2019;s disease. Biomark. Med. 2012;6:431&#x2013;439. doi: 10.2217/bmm.12.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.12.51</ArticleId><ArticleId IdType="pubmed">22917145</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratic&#xf2; D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001;21:4183&#x2013;4187. doi: 10.1523/JNEUROSCI.21-12-04183.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-12-04183.2001</ArticleId><ArticleId IdType="pmc">PMC6762743</ArticleId><ArticleId IdType="pubmed">11404403</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros R., LaFerla F.M. Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony. Exp. Neurol. 2013;239:133&#x2013;138. doi: 10.1016/j.expneurol.2012.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.10.007</ArticleId><ArticleId IdType="pubmed">23063604</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhong C. Decoding Alzheimer&#x2019;s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013;108:21&#x2013;43. doi: 10.1016/j.pneurobio.2013.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.06.004</ArticleId><ArticleId IdType="pubmed">23850509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hroudov&#xe1; J., Singh N., Fi&#x161;ar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer&#x2019;s disease. Biomed. Res. Int. 2014;2014:175062. doi: 10.1155/2014/175062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/175062</ArticleId><ArticleId IdType="pmc">PMC4036420</ArticleId><ArticleId IdType="pubmed">24900954</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho C., Correia S.C., Santos R.X., Cardoso S., Moreira P.I., Clark T.A., Zhu X., Smith M.A., Perry G. Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J. Bioenerg. Biomembr. 2009;41:433&#x2013;440. doi: 10.1007/s10863-009-9247-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-009-9247-1</ArticleId><ArticleId IdType="pmc">PMC4054815</ArticleId><ArticleId IdType="pubmed">19830532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.S., Adriaanse B.A., Greig N.H., Mattson M.P., Cader M.Z., Bohr V.A., Fang E.F. Mitophagy and Alzheimer&#x2019;s disease: Cellular and molecular mechanisms. Trends Neurosci. 2017;40:151&#x2013;166. doi: 10.1016/j.tins.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2017.01.002</ArticleId><ArticleId IdType="pmc">PMC5341618</ArticleId><ArticleId IdType="pubmed">28190529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanni C., Nardinocchi L., Puca R., Stanga S., Uberti D., Memo M., Govoni S., D&#x2019;Orazi G., Racchi M. Homeodomain interacting protein kinase 2: A target for Alzheimer&#x2019;s beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS ONE. 2010;5:e10171. doi: 10.1371/journal.pone.0010171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010171</ArticleId><ArticleId IdType="pmc">PMC2854690</ArticleId><ArticleId IdType="pubmed">20418953</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez M.J., Ponce D.P., Aranguiz A., Behrens M.I., Quintanilla R.A. Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer&#x2019;s disease. Redox Biol. 2018;19:290&#x2013;300. doi: 10.1016/j.redox.2018.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.09.001</ArticleId><ArticleId IdType="pmc">PMC6129674</ArticleId><ArticleId IdType="pubmed">30199818</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanga S., Zanou N., Audouard E., Tasiaux B., Contino S., Vandermeulen G., Ren&#xe9; F., Loeffler J.P., Clotman F., Gailly P., et al. APP-dependent glial cell line-derived neurotrophic factor gene expression drives neuromuscular junction formation. FASEB J. 2016;30:1696&#x2013;1711. doi: 10.1096/fj.15-278739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.15-278739</ArticleId><ArticleId IdType="pubmed">26718890</ArticleId></ArticleIdList></Reference><Reference><Citation>Contino S., Porporato P.E., Bird M., Marinangeli C., Opsomer R., Sonveaux P., Bontemps F., Dewachter I., Octave J.N., Bertrand L., et al. Presenilin 2-dependent maintenance of mitochondrial oxidative capacity and morphology. Front. Physiol. 2017;8:796. doi: 10.3389/fphys.2017.00796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00796</ArticleId><ArticleId IdType="pmc">PMC5650731</ArticleId><ArticleId IdType="pubmed">29085303</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanga S., Brambilla L., Tasiaux B., Dang A.H., Ivanoiu A., Octave J.N., Rossi D., van Pesch V., Kienlen-Campard P. A Role for GDNF and soluble APP as biomarkers of amyotrophic lateral sclerosis pathophysiology. Front. Neurol. 2018;9:384. doi: 10.3389/fneur.2018.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00384</ArticleId><ArticleId IdType="pmc">PMC5988896</ArticleId><ArticleId IdType="pubmed">29899726</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047. doi: 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Lewis P., Revesz T., Lees A., Paisan-Ruiz C. The genetics of Parkinson&#x2019;s syndromes: A critical review. Curr. Opin. Genet. Dev. 2009;19:254&#x2013;265. doi: 10.1016/j.gde.2009.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2009.03.008</ArticleId><ArticleId IdType="pubmed">19419854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006;38:515&#x2013;517. doi: 10.1038/ng1769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1769</ArticleId><ArticleId IdType="pubmed">16604074</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x2019;s and Alzheimer&#x2019;s disease brains. Neurology. 1988;38:1285&#x2013;1291. doi: 10.1212/WNL.38.8.1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.38.8.1285</ArticleId><ArticleId IdType="pubmed">3399080</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson&#x2019;s disease. Neurobiol. Dis. 2006;21:404&#x2013;412. doi: 10.1016/j.nbd.2005.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.08.002</ArticleId><ArticleId IdType="pubmed">16182554</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979&#x2013;980. doi: 10.1126/science.6823561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6823561</ArticleId><ArticleId IdType="pubmed">6823561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795. doi: 10.1038/nature05292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05292</ArticleId><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose A., Beal M.F. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson&#x2019;s disease. Eur. J. Neurosci. 2019;49:525&#x2013;532. doi: 10.1111/ejn.14264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14264</ArticleId><ArticleId IdType="pubmed">30408242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ndorf D.C., Ivanyuk D., Baden P., Sanchez-Martinez A., De Cicco S., Yu C., Giunta I., Schwarz L.K., Di Napoli G., Panagiotakopoulou V., et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson&#x2019;s disease. Cell Rep. 2018;23:2976&#x2013;2988. doi: 10.1016/j.celrep.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.05.009</ArticleId><ArticleId IdType="pubmed">29874584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosley R.L., Hutter-Saunders J.A., Stone D.K., Gendelman H.E. Inflammation and adaptive immunity in Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2012;2:a009381. doi: 10.1101/cshperspect.a009381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009381</ArticleId><ArticleId IdType="pmc">PMC3253034</ArticleId><ArticleId IdType="pubmed">22315722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose A., Beal M.F. Mitochondrial dysfunction in Parkinson&#x2019;s disease. J. Neurochem. 2016;139:216&#x2013;231. doi: 10.1111/jnc.13731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13731</ArticleId><ArticleId IdType="pubmed">27546335</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson&#x2019;s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006;26:5256&#x2013;5264. doi: 10.1523/JNEUROSCI.0984-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0984-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674236</ArticleId><ArticleId IdType="pubmed">16687518</ArticleId></ArticleIdList></Reference><Reference><Citation>Perier C., Bov&#xe9; J., Dehay B., Jackson-Lewis V., Rabinovitch P.S., Przedborski S., Vila M. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to Parkinsonian neurotoxins. Ann. Neurol. 2010;68:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">20695011</ArticleId></ArticleIdList></Reference><Reference><Citation>Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol. Life Sci. 2008;65:1272&#x2013;1284. doi: 10.1007/s00018-008-7589-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-7589-1</ArticleId><ArticleId IdType="pubmed">18322646</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., Sheu S.S. Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 2004;287:C817&#x2013;C833. doi: 10.1152/ajpcell.00139.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00139.2004</ArticleId><ArticleId IdType="pubmed">15355853</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., J&#xe4;ger S., Handschin C., Zheng K., Lin J., Yang W., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397&#x2013;408. doi: 10.1016/j.cell.2006.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.09.024</ArticleId><ArticleId IdType="pubmed">17055439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., Eklund A.C., Zhang-James Y., Kim P.D., Hauser M.A., et al. PGC-1&#x3b1;, a potential therapeutic target for early intervention in Parkinson&#x2019;s disease. Sci. Transl. Med. 2010;2:52ra73. doi: 10.1126/scitranslmed.3001059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001059</ArticleId><ArticleId IdType="pmc">PMC3129986</ArticleId><ArticleId IdType="pubmed">20926834</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthet A., Margolis E.B., Zhang J., Hsieh I., Hnasko T.S., Ahmad J., Edwards R.H., Sesaki H., Huang E.J., Nakamura K. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J. Neurosci. 2014;34:14304&#x2013;14317. doi: 10.1523/JNEUROSCI.0930-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0930-14.2014</ArticleId><ArticleId IdType="pmc">PMC4205554</ArticleId><ArticleId IdType="pubmed">25339743</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarffe L.A., Stevens D.A., Dawson V.L., Dawson T.M. Parkin and PINK1: Much more than mitophagy. Trends Neurosci. 2014;37:315&#x2013;324. doi: 10.1016/j.tins.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4075431</ArticleId><ArticleId IdType="pubmed">24735649</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi R.K., Beal M.F. Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci. 2008;1147:395&#x2013;412. doi: 10.1196/annals.1427.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1427.027</ArticleId><ArticleId IdType="pmc">PMC2605644</ArticleId><ArticleId IdType="pubmed">19076459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington&#x2019;s disease. J. Neuropathol. Exp. Neurol. 1985;44:559&#x2013;577. doi: 10.1097/00005072-198511000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198511000-00003</ArticleId><ArticleId IdType="pubmed">2932539</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Charles V., Williams M., Miller G., Whetsell W.O., Tagle D.A. Transgenic mice expressing mutated full-length HD cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington&#x2019;s disease. Philos. Trans. R Soc. Lond. B Biol. Sci. 1999;354:1035&#x2013;1045. doi: 10.1098/rstb.1999.0456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1999.0456</ArticleId><ArticleId IdType="pmc">PMC1692609</ArticleId><ArticleId IdType="pubmed">10434303</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Li X.J. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol. Neurodegener. 2006;1:19. doi: 10.1186/1750-1326-1-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-1-19</ArticleId><ArticleId IdType="pmc">PMC1764744</ArticleId><ArticleId IdType="pubmed">17173700</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne S.E., Beal M.F. The energetics of Huntington&#x2019;s disease. Neurochem. Res. 2004;29:531&#x2013;546. doi: 10.1023/B:NERE.0000014824.04728.dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:NERE.0000014824.04728.dd</ArticleId><ArticleId IdType="pubmed">15038601</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui H., Moraes C.T. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. Hum. Mol. Genet. 2007;16:783&#x2013;797. doi: 10.1093/hmg/ddm023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm023</ArticleId><ArticleId IdType="pubmed">17356014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang S., Disatnik M.H., Mochly-Rosen D. Impaired GAPDH-induced mitophagy contributes to the pathology of Huntington&#x2019;s disease. EMBO Mol. Med. 2015;7:1307&#x2013;1326. doi: 10.15252/emmm.201505256.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201505256</ArticleId><ArticleId IdType="pmc">PMC4604685</ArticleId><ArticleId IdType="pubmed">26268247</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo-Torres K., Berr&#xed;os L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington&#x2019;s disease. DNA Repair. 2009;8:126&#x2013;136. doi: 10.1016/j.dnarep.2008.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2008.09.004</ArticleId><ArticleId IdType="pmc">PMC3268004</ArticleId><ArticleId IdType="pubmed">18935984</ArticleId></ArticleIdList></Reference><Reference><Citation>Banoei M.M., Houshmand M., Panahi M.S., Shariati P., Rostami M., Manshadi M.D., Majidizadeh T. Huntington&#x2019;s disease and mitochondrial DNA deletions: Event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?! Cell Mol. Neurobiol. 2007;27:867&#x2013;875. doi: 10.1007/s10571-007-9206-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-007-9206-5</ArticleId><ArticleId IdType="pubmed">17952586</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A., Glass C.K. The choreography of neuroinflammation in Huntington&#x2019;s disease. Trends Immunol. 2015;36:364&#x2013;373. doi: 10.1016/j.it.2015.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC4786070</ArticleId><ArticleId IdType="pubmed">26001312</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L. Inactivation of the mouse Huntington&#x2019;s disease gene homolog Hdh. Science. 1995;269:407&#x2013;410. doi: 10.1126/science.7618107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7618107</ArticleId><ArticleId IdType="pubmed">7618107</ArticleId></ArticleIdList></Reference><Reference><Citation>Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2005;102:11023&#x2013;11028. doi: 10.1073/pnas.0504921102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504921102</ArticleId><ArticleId IdType="pmc">PMC1182457</ArticleId><ArticleId IdType="pubmed">16043692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihm M.J., Amann D.M., Schanbacher B.L., Altschuld R.A., Bauer J.A., Hoyt K.R. Cardiac dysfunction in the R6/2 mouse model of Huntington&#x2019;s disease. Neurobiol. Dis. 2007;25:297&#x2013;308. doi: 10.1016/j.nbd.2006.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.09.016</ArticleId><ArticleId IdType="pmc">PMC1850107</ArticleId><ArticleId IdType="pubmed">17126554</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer L.A. Diabetes mellitus in Huntington disease. Clin. Genet. 1985;27:62&#x2013;67. doi: 10.1111/j.1399-0004.1985.tb00185.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.1985.tb00185.x</ArticleId><ArticleId IdType="pubmed">3156696</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse M.E., Hughes G., Wiles C.M., Rosser A.E. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington&#x2019;s disease. J. Neurol. 2008;255:1534&#x2013;1540. doi: 10.1007/s00415-008-0964-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-008-0964-x</ArticleId><ArticleId IdType="pubmed">19005627</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#x119;drak P., Mozolewski P., W&#x119;grzyn G., Wi&#x119;ckowski M.R. Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington&#x2019;s disease patients. Metab. Brain Dis. 2018;33:2005&#x2013;2017. doi: 10.1007/s11011-018-0308-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0308-1</ArticleId><ArticleId IdType="pmc">PMC6244791</ArticleId><ArticleId IdType="pubmed">30120672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.M., Wu Y.R., Chang K.H. Altered aconitase 2 activity in Huntington&#x2019;s disease peripheral blood cells and mouse model striatum. Int. J. Mol. Sci. 2017;18:2480. doi: 10.3390/ijms18112480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18112480</ArticleId><ArticleId IdType="pmc">PMC5713446</ArticleId><ArticleId IdType="pubmed">29160844</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Bowser R., Bruijn L., Dupuis L., Ludolph A., McGrath M., Manfredi G., Maragakis N., Miller R.G., Pullman S.L., et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013;14:19&#x2013;32. doi: 10.3109/21678421.2013.778554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778554</ArticleId><ArticleId IdType="pmc">PMC4284067</ArticleId><ArticleId IdType="pubmed">23678877</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Ferri A., Carr&#xec; M.T. Amyotrophic lateral sclerosis: From current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 2008;10:405&#x2013;443. doi: 10.1089/ars.2007.1760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1760</ArticleId><ArticleId IdType="pubmed">18370853</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996;139:27&#x2013;33. doi: 10.1016/0022-510X(96)00073-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992;140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007;66:10&#x2013;16. doi: 10.1097/nen.0b013e31802c396b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802c396b</ArticleId><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P., Gal J., Kwinter D.M., Liu X., Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2010;1802:45&#x2013;51. doi: 10.1016/j.bbadis.2009.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2009.08.012</ArticleId><ArticleId IdType="pmc">PMC2790551</ArticleId><ArticleId IdType="pubmed">19715760</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Belford M.E., Lennon N., Bacskai B.J., Hyman B.T., Trotti D., Brown R.H. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19&#x2013;30. doi: 10.1016/j.neuron.2004.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.06.021</ArticleId><ArticleId IdType="pubmed">15233914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.L., Oudart H., de Tapia M., Barbeito L., Loeffler J.P. Mitochondria in amyotrophic lateral sclerosis: A trigger and a target. Neurodegener. Dis. 2004;1:245&#x2013;254. doi: 10.1159/000085063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085063</ArticleId><ArticleId IdType="pubmed">16908975</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E., Goldsteins G., Bart G., Koistinaho J., Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front. Cell Neurosci. 2014;8:131. doi: 10.3389/fncel.2014.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00131</ArticleId><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W., Pasinelli P., Trotti D. Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2014;1842:1295&#x2013;1301. doi: 10.1016/j.bbadis.2014.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.02.009</ArticleId><ArticleId IdType="pmc">PMC4074562</ArticleId><ArticleId IdType="pubmed">24568860</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfawy H.A., Das B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. Life Sci. 2019;218:165&#x2013;184. doi: 10.1016/j.lfs.2018.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2018.12.029</ArticleId><ArticleId IdType="pubmed">30578866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA. 1999;96:6307&#x2013;6311. doi: 10.1073/pnas.96.11.6307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.11.6307</ArticleId><ArticleId IdType="pmc">PMC26877</ArticleId><ArticleId IdType="pubmed">10339583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripolone M., Ronchi D., Violano R., Vallejo D., Fagiolari G., Barca E., Lucchini V., Colombo I., Villa L., Berardinelli A., et al. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol. 2015;72:666&#x2013;675. doi: 10.1001/jamaneurol.2015.0178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0178</ArticleId><ArticleId IdType="pmc">PMC4944827</ArticleId><ArticleId IdType="pubmed">25844556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya S., Boes S. Correction to: Measuring quality of life in children with spinal muscular atrophy: A systematic literature review. Qual. Life Res. 2018;27:3095. doi: 10.1007/s11136-018-1975-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-018-1975-4</ArticleId><ArticleId IdType="pubmed">30218211</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller H.R., Gillingwater T.H., Wishart T.M. Commonality amid diversity: Multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy. Neuromuscul. Disord. 2016;26:560&#x2013;569. doi: 10.1016/j.nmd.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2016.06.004</ArticleId><ArticleId IdType="pubmed">27460344</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd P.J., Tu W.Y., Shorrock H.K., Groen E.J.N., Carter R.N., Powis R.A., Thomson S.R., Thomson D., Graham L.C., Motyl A.A.L., et al. Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 2017;13:e1006744. doi: 10.1371/journal.pgen.1006744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006744</ArticleId><ArticleId IdType="pmc">PMC5417717</ArticleId><ArticleId IdType="pubmed">28426667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliardini S., Giavazzi A., Setola V., Lizier C., Di Luca M., DeBiasi S., Battaglia G. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Hum. Mol. Genet. 2000;9:47&#x2013;56. doi: 10.1093/hmg/9.1.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.1.47</ArticleId><ArticleId IdType="pubmed">10587577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotti F., Imlach W.L., Saieva L., Beck E.S., Hao L.T., Li D.K., Jiao W., Mentis G.Z., Beattie C.E., McCabe B.D., et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell. 2012;151:440&#x2013;454. doi: 10.1016/j.cell.2012.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.09.012</ArticleId><ArticleId IdType="pmc">PMC3474596</ArticleId><ArticleId IdType="pubmed">23063131</ArticleId></ArticleIdList></Reference><Reference><Citation>Boido M., Vercelli A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front. Neuroanat. 2016;10:6. doi: 10.3389/fnana.2016.00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2016.00006</ArticleId><ArticleId IdType="pmc">PMC4737916</ArticleId><ArticleId IdType="pubmed">26869891</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadimitriou D., Le Verche V., Jacquier A., Ikiz B., Przedborski S., Re D.B. Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol. Dis. 2010;37:493&#x2013;502. doi: 10.1016/j.nbd.2009.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.10.005</ArticleId><ArticleId IdType="pmc">PMC2823924</ArticleId><ArticleId IdType="pubmed">19833209</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone C., Ramirez A., Bucchia M., Rinchetti P., Rideout H., Papadimitriou D., Re D.B., Corti S. Is spinal muscular atrophy a disease of the motor neurons only: Pathogenesis and therapeutic implications? Cell Mol. Life Sci. 2016;73:1003&#x2013;1020. doi: 10.1007/s00018-015-2106-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2106-9</ArticleId><ArticleId IdType="pmc">PMC4756905</ArticleId><ArticleId IdType="pubmed">26681261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubowitz V. Muscle disorders in childhood. Major Probl. Clin. Pediatr. 1978;16:1&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">661378</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C.C., Denton K.R., Wang Z.B., Zhang X., Li X.J. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. Dis. Model. Mech. 2016;9:39&#x2013;49. doi: 10.1242/dmm.021766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.021766</ArticleId><ArticleId IdType="pmc">PMC4728333</ArticleId><ArticleId IdType="pubmed">26586529</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia D., Malena A., Spinazzi M., Desbats M.A., Salviati L., Russell A.P., Miotto G., Tosatto L., Pegoraro E., Sorar&#xf9; G., et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum. Mol. Genet. 2017;26:1087&#x2013;1103. doi: 10.1093/hmg/ddx019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx019</ArticleId><ArticleId IdType="pmc">PMC5409076</ArticleId><ArticleId IdType="pubmed">28087734</ArticleId></ArticleIdList></Reference><Reference><Citation>Acsadi G., Lee I., Li X., Khaidakov M., Pecinova A., Parker G.C., H&#xfc;ttemann M. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J. Neurosci. Res. 2009;87:2748&#x2013;2756. doi: 10.1002/jnr.22106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22106</ArticleId><ArticleId IdType="pubmed">19437551</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifani N. Motor neurons and the generation of spinal motor neuron diversity. Front. Cell Neurosci. 2014;8:293. doi: 10.3389/fncel.2014.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00293</ArticleId><ArticleId IdType="pmc">PMC4191298</ArticleId><ArticleId IdType="pubmed">25346659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijngaarde C.A., Blank A.C., Stam M., Wadman R.I., van den Berg L.H., van der Pol W.L. Cardiac pathology in spinal muscular atrophy: A systematic review. Orphanet. J. Rare Dis. 2017;12:67. doi: 10.1186/s13023-017-0613-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-017-0613-5</ArticleId><ArticleId IdType="pmc">PMC5387385</ArticleId><ArticleId IdType="pubmed">28399889</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortune M.D., Guo H., Burren O., Schofield E., Walker N.M., Ban M., Sawcer S.J., Bowes J., Worthington J., Barton A., et al. Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. Nat. Genet. 2015;47:839&#x2013;846. doi: 10.1038/ng.3330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3330</ArticleId><ArticleId IdType="pmc">PMC4754941</ArticleId><ArticleId IdType="pubmed">26053495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B.C., Ye C.J., Price A.L., Zaitlen N., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium Transethnic genetic-correlation estimates from summary statistics. Am. J. Hum. Genet. 2016;99:76&#x2013;88. doi: 10.1016/j.ajhg.2016.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.05.001</ArticleId><ArticleId IdType="pmc">PMC5005434</ArticleId><ArticleId IdType="pubmed">27321947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickrell J.K., Berisa T., Liu J.Z., S&#xe9;gurel L., Tung J.Y., Hinds D.A. Detection and interpretation of shared genetic influences on 42 human traits. Nat. Genet. 2016;48:709&#x2013;717. doi: 10.1038/ng.3570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3570</ArticleId><ArticleId IdType="pmc">PMC5207801</ArticleId><ArticleId IdType="pubmed">27182965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu L., Chan K.H.K., Zhang G., Huan T., Kurt Z., Zhao Y., Codoni V., Tr&#xe9;gou&#xeb;t D.A., Yang J., Wilson J.G., et al. Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States. PLoS Genet. 2017;13:e1007040. doi: 10.1371/journal.pgen.1007040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007040</ArticleId><ArticleId IdType="pmc">PMC5634657</ArticleId><ArticleId IdType="pubmed">28957322</ArticleId></ArticleIdList></Reference><Reference><Citation>Arneson D., Zhang Y., Yang X., Narayanan M. Shared mechanisms among neurodegenerative diseases: From genetic factors to gene networks. J. Genet. 2018;97:795&#x2013;806. doi: 10.1007/s12041-018-0963-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12041-018-0963-3</ArticleId><ArticleId IdType="pmc">PMC6211183</ArticleId><ArticleId IdType="pubmed">30027910</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.C., Lockwood A.H., Sonawane B.R. Neurodegenerative diseases: An overview of environmental risk factors. Environ. Health Perspect. 2005;113:1250&#x2013;1256. doi: 10.1289/ehp.7567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.7567</ArticleId><ArticleId IdType="pmc">PMC1280411</ArticleId><ArticleId IdType="pubmed">16140637</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhre O., Utkilen H., Duale N., Brunborg G., Hofer T. Metal dyshomeostasis and inflammation in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: Possible impact of environmental exposures. Oxid. Med. Cell Longev. 2013;2013:726954. doi: 10.1155/2013/726954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/726954</ArticleId><ArticleId IdType="pmc">PMC3654362</ArticleId><ArticleId IdType="pubmed">23710288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler N.R., Sramek J.J. Review of the next generation of Alzheimer&#x2019;s disease therapeutics: Challenges for drug development. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2001;25:27&#x2013;57. doi: 10.1016/S0278-5846(00)00147-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0278-5846(00)00147-0</ArticleId><ArticleId IdType="pubmed">11263756</ArticleId></ArticleIdList></Reference><Reference><Citation>Poga&#x10d;nik L., Ota A., Ulrih N.P. An overview of crucial dietary substances and their modes of action for prevention of neurodegenerative diseases. Cells. 2020;9:576. doi: 10.3390/cells9030576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9030576</ArticleId><ArticleId IdType="pmc">PMC7140513</ArticleId><ArticleId IdType="pubmed">32121302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins H.M., Morris J.K. New therapeutics to modulate mitochondrial function in neurodegenerative disorders. Curr. Pharm. Des. 2017;23:731&#x2013;752. doi: 10.2174/1381612822666161230144517.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666161230144517</ArticleId><ArticleId IdType="pmc">PMC5466080</ArticleId><ArticleId IdType="pubmed">28034353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy S.M. Nusinersen: First global approval. Drugs. 2017;77:473&#x2013;479. doi: 10.1007/s40265-017-0711-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0711-7</ArticleId><ArticleId IdType="pubmed">28229309</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin K.T., Potkin S.G. New directions in therapeutics for Huntington disease. Future Neurol. 2018;13:101&#x2013;121. doi: 10.2217/fnl-2017-0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fnl-2017-0035</ArticleId><ArticleId IdType="pmc">PMC6378950</ArticleId><ArticleId IdType="pubmed">30800004</ArticleId></ArticleIdList></Reference><Reference><Citation>Atri A. Current and future treatments in Alzheimer&#x2019;s disease. Semin. Neurol. 2019;39:227&#x2013;240. doi: 10.1055/s-0039-1678581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1678581</ArticleId><ArticleId IdType="pubmed">30925615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy S.M. Onasemnogene abeparvovec: First global approval. Drugs. 2019;79:1255&#x2013;1262. doi: 10.1007/s40265-019-01162-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01162-5</ArticleId><ArticleId IdType="pubmed">31270752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich S.G., Savitt J.M. Parkinson&#x2019;s disease. Med. Clin. North. Am. 2019;103:337&#x2013;350. doi: 10.1016/j.mcna.2018.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2018.10.014</ArticleId><ArticleId IdType="pubmed">30704685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenini G., Voos W. Mitochondria as potential targets in Alzheimer disease therapy: An update. Front. Pharmacol. 2019;10:902. doi: 10.3389/fphar.2019.00902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00902</ArticleId><ArticleId IdType="pmc">PMC6716473</ArticleId><ArticleId IdType="pubmed">31507410</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y., Carbonell F.M., Sotero R.C., Chouinard-Decorte F., Evans A.C., Alzheimer&#x2019;s Disease Neuroimaging Initiative Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer&#x2019;s disease. Neuroimage. 2017;152:60&#x2013;77. doi: 10.1016/j.neuroimage.2017.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.02.058</ArticleId><ArticleId IdType="pubmed">28257929</ArticleId></ArticleIdList></Reference><Reference><Citation>Veitch D.P., Weiner M.W., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Harvey D., Jack C.R., Jagust W., Morris J.C., et al. Understanding disease progression and improving Alzheimer&#x2019;s disease clinical trials: Recent highlights from the Alzheimer&#x2019;s disease neuroimaging initiative. Alzheimers Dement. 2019;15:106&#x2013;152. doi: 10.1016/j.jalz.2018.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.08.005</ArticleId><ArticleId IdType="pubmed">30321505</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss D.E., Perez R.G., Kobayashi H. Cholinesterase inhibitor therapy in Alzheimer&#x2019;s disease: The limits and tolerability of irreversible CNS-selective acetylcholinesterase inhibition in primates. J. Alzheimers Dis. 2017;55:1285&#x2013;1294. doi: 10.3233/JAD-160733.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160733</ArticleId><ArticleId IdType="pmc">PMC5148699</ArticleId><ArticleId IdType="pubmed">27858711</ArticleId></ArticleIdList></Reference><Reference><Citation>Folch J., Busquets O., Ettcheto M., S&#xe1;nchez-L&#xf3;pez E., Castro-Torres R.D., Verdaguer E., Garcia M.L., Olloquequi J., Casades&#xfa;s G., Beas-Zarate C., et al. Memantine for the treatment of dementia: A review on its current and future applications. J. Alzheimers Dis. 2018;62:1223&#x2013;1240. doi: 10.3233/JAD-170672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170672</ArticleId><ArticleId IdType="pmc">PMC5870028</ArticleId><ArticleId IdType="pubmed">29254093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K. Cholinesterase inhibitors as Alzheimer&#x2019;s therapeutics (review) Mol. Med. Rep. 2019;20:1479&#x2013;1487. doi: 10.3892/mmr.2019.10374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2019.10374</ArticleId><ArticleId IdType="pmc">PMC6625431</ArticleId><ArticleId IdType="pubmed">31257471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascol O., Payoux P., Ory F., Ferreira J.J., Brefel-Courbon C., Montastruc J.L. Limitations of current Parkinson&#x2019;s disease therapy. Ann. Neurol. 2003;53:S3&#x2013;S12. doi: 10.1002/ana.10513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10513</ArticleId><ArticleId IdType="pubmed">12666094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong M., Ba M., Ren C., Yu L., Dong S., Yu G., Liang H. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson&#x2019;s disease. Oncotarget. 2017;8:57316&#x2013;57326. doi: 10.18632/oncotarget.17622.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.17622</ArticleId><ArticleId IdType="pmc">PMC5593643</ArticleId><ArticleId IdType="pubmed">28915672</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairoalsindi O.A., Abuzinadah A.R. Maximizing the survival of amyotrophic lateral sclerosis patients: Current perspectives. Neurol. Res. Int. 2018;2018:6534150. doi: 10.1155/2018/6534150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6534150</ArticleId><ArticleId IdType="pmc">PMC6109498</ArticleId><ArticleId IdType="pubmed">30159171</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangouloff T., Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives. Ther. Clin. Risk Manag. 2019;15:1153&#x2013;1161. doi: 10.2147/TCRM.S172291.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S172291</ArticleId><ArticleId IdType="pmc">PMC6778729</ArticleId><ArticleId IdType="pubmed">31632042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzino G., Irrera N., Cucinotta M., Pallio G., Mannino F., Arcoraci V., Squadrito F., Altavilla D., Bitto A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8416763</ArticleId><ArticleId IdType="pmc">PMC5551541</ArticleId><ArticleId IdType="pubmed">28819546</ArticleId></ArticleIdList></Reference><Reference><Citation>Morat&#xf3; L., Bertini E., Verrigni D., Ardissone A., Ruiz M., Ferrer I., Uziel G., Pujol A. Mitochondrial dysfunction in central nervous system white matter disorders. Glia. 2014;62:1878&#x2013;1894. doi: 10.1002/glia.22670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22670</ArticleId><ArticleId IdType="pubmed">24865954</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrera-Juli&#xe1; S., Moreno M.L., Barrios C., de la Rubia Ort&#xed; J.E., Drehmer E. Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: A comprehensive review. Front. Physiol. 2020;11:63. doi: 10.3389/fphys.2020.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00063</ArticleId><ArticleId IdType="pmc">PMC7016185</ArticleId><ArticleId IdType="pubmed">32116773</ArticleId></ArticleIdList></Reference><Reference><Citation>Innamorato N.G., Lastres-Becker I., Cuadrado A. Role of microglial redox balance in modulation of neuroinflammation. Curr. Opin. Neurol. 2009;22:308&#x2013;314. doi: 10.1097/WCO.0b013e32832a3225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32832a3225</ArticleId><ArticleId IdType="pubmed">19359988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007;14:1189&#x2013;1197. doi: 10.2174/092986707780597961.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986707780597961</ArticleId><ArticleId IdType="pubmed">17504139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A., Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J. Biol. Chem. 2001;276:4588&#x2013;4596. doi: 10.1074/jbc.M009093200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M009093200</ArticleId><ArticleId IdType="pubmed">11092892</ArticleId></ArticleIdList></Reference><Reference><Citation>Young M.L., Franklin J.L. The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. Mol. Cell Neurosci. 2019;101:103409. doi: 10.1016/j.mcn.2019.103409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2019.103409</ArticleId><ArticleId IdType="pmc">PMC7359863</ArticleId><ArticleId IdType="pubmed">31521745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y., Feng D., Tao K., Wang R., Shi Y., Qin H., Murphy M.P., Yang Q., Zhao G. MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1&#x3b1;. Biochim. Biophys. Acta Mol. Basis Dis. 2018;1864:2859&#x2013;2870. doi: 10.1016/j.bbadis.2018.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.05.018</ArticleId><ArticleId IdType="pubmed">29842922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald A., Kumar K.R., Sue C.M. New insights into the complex role of mitochondria in Parkinson&#x2019;s disease. Prog. Neurobiol. 2019;177:73&#x2013;93. doi: 10.1016/j.pneurobio.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2018.09.003</ArticleId><ArticleId IdType="pubmed">30219247</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E., Cassina A., Mart&#xed;nez-Palma L., Souza J.M., Bolatto C., Rodr&#xed;guez-Bottero S., Logan A., Smith R.A., Murphy M.P., Barbeito L., et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2014;70:204&#x2013;213. doi: 10.1016/j.freeradbiomed.2014.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.02.019</ArticleId><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinho B.R., Duarte A.I., Canas P.M., Moreira P.I., Murphy M.P., Oliveira J.M.A. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington&#x2019;s disease mice. Free Radic. Biol. Med. 2020;146:372&#x2013;382. doi: 10.1016/j.freeradbiomed.2019.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.11.021</ArticleId><ArticleId IdType="pmc">PMC6970224</ArticleId><ArticleId IdType="pubmed">31751762</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissig V. Drug development for the therapy of mitochondrial diseases. Trends Mol. Med. 2020;26:40&#x2013;57. doi: 10.1016/j.molmed.2019.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.09.002</ArticleId><ArticleId IdType="pubmed">31727544</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova N.A., Muraleva N.A., Maksimova K.Y., Rudnitskaya E.A., Kiseleva E., Telegina D.V., Kolosova N.G. An antioxidant specifically targeting mitochondria delays progression of Alzheimer&#x2019;s disease-like pathology. Aging. 2016;8:2713&#x2013;2733. doi: 10.18632/aging.101054.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101054</ArticleId><ArticleId IdType="pmc">PMC5191865</ArticleId><ArticleId IdType="pubmed">27750209</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenza T.M., Ghaisas S., Ramirez J.E.V., Harischandra D., Anantharam V., Kalyanaraman B., Kanthasamy A.G., Narasimhan B. Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine. 2017;13:809&#x2013;820. doi: 10.1016/j.nano.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2016.10.004</ArticleId><ArticleId IdType="pmc">PMC5392427</ArticleId><ArticleId IdType="pubmed">27771430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Langley M.R., Harischandra D.S., Neal M.L., Jin H., Anantharam V., Joseph J., Brenza T., Narasimhan B., Kanthasamy A., et al. Mitoapocynin treatment protects against neuroinflammation and dopaminergic neurodegeneration in a preclinical animal model of Parkinson&#x2019;s disease. J. Neuroimmune Pharmacol. 2016;11:259&#x2013;278. doi: 10.1007/s11481-016-9650-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-016-9650-4</ArticleId><ArticleId IdType="pmc">PMC4995106</ArticleId><ArticleId IdType="pubmed">26838361</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley M., Ghosh A., Charli A., Sarkar S., Ay M., Luo J., Zielonka J., Brenza T., Bennett B., Jin H., et al. Mito-apocynin prevents mitochondrial dysfunction, microglial activation, oxidative damage, and progressive neurodegeneration in MitoPark transgenic mice. Antioxid. Redox Signal. 2017;27:1048&#x2013;1066. doi: 10.1089/ars.2016.6905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2016.6905</ArticleId><ArticleId IdType="pmc">PMC5651937</ArticleId><ArticleId IdType="pubmed">28375739</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosmann B., Skutella T., Beyer K., Behl C. Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol. Chem. 2001;382:1601&#x2013;1612. doi: 10.1515/BC.2001.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/BC.2001.195</ArticleId><ArticleId IdType="pubmed">11767950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachurin S.O., Makhaeva G.F., Shevtsova E.F., Boltneva N.P., Kovaleva N.V., Lushchekina S.V., Rudakova E.V., Dubova L.G., Vinogradova D.V., Sokolov V.B., et al. Conjugates of methylene blue with &#x3b3;-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases. Sci. Rep. 2019;9:4873. doi: 10.1038/s41598-019-41272-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41272-4</ArticleId><ArticleId IdType="pmc">PMC6424957</ArticleId><ArticleId IdType="pubmed">30890752</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.S., Clark M.E., Hardy G.A., Kraan D.J., Biondo E., Gonzalez-Lima F., Cormack L.K., Monfils M., Lee H.J. Daily consumption of methylene blue reduces attentional deficits and dopamine reduction in a 6-OHDA model of Parkinson&#x2019;s disease. Neuroscience. 2017;359:8&#x2013;16. doi: 10.1016/j.neuroscience.2017.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.07.001</ArticleId><ArticleId IdType="pubmed">28694175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha M., Hernandez-Mijares A., Garcia-Malpartida K., Ba&#xf1;uls C., Bellod L., Victor V.M. Mitochondria-targeted antioxidant peptides. Curr. Pharm. Des. 2010;16:3124&#x2013;3131. doi: 10.2174/138161210793292519.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210793292519</ArticleId><ArticleId IdType="pubmed">20687871</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto H.H., Birk A.V. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin. Pharmacol. Ther. 2014;96:672&#x2013;683. doi: 10.1038/clpt.2014.174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2014.174</ArticleId><ArticleId IdType="pmc">PMC4267688</ArticleId><ArticleId IdType="pubmed">25188726</ArticleId></ArticleIdList></Reference><Reference><Citation>Searls R.L., Sanadi D.R. &#x3b1;-Ketoglutaric dehydrogenase. VIII. Isolation and some properties of a flavoprotein component. J. Biol. Chem. 1960;235:2485&#x2013;2491.</Citation><ArticleIdList><ArticleId IdType="pubmed">14444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos S.M., Romeiro C.F.R., Rodrigues C.A., Cerqueira A.R.L., Monteiro M.C. Mitochondrial dysfunction and alpha-lipoic acid: Beneficial or harmful in Alzheimer&#x2019;s disease? Oxid. Med. Cell Longev. 2019;2019:8409329. doi: 10.1155/2019/8409329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8409329</ArticleId><ArticleId IdType="pmc">PMC6914903</ArticleId><ArticleId IdType="pubmed">31885820</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Shu H.Y., Huang T., Zhang Q.L., Li D., Zhang G.Q., Peng X.Y., Liu C.F., Luo W.F., Hu L.F. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE. 2014;9:e100286. doi: 10.1371/journal.pone.0100286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100286</ArticleId><ArticleId IdType="pmc">PMC4069024</ArticleId><ArticleId IdType="pubmed">24959672</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Schwarzschild M.A. Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics. 2017;14:148&#x2013;153. doi: 10.1007/s13311-016-0497-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0497-4</ArticleId><ArticleId IdType="pmc">PMC5233635</ArticleId><ArticleId IdType="pubmed">27995438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzschild M.A., Ascherio A., Beal M.F., Cudkowicz M.E., Curhan G.C., Hare J.M., Hooper D.C., Kieburtz K.D., Macklin E.A., Oakes D., et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial. JAMA Neurol. 2014;71:141&#x2013;150. doi: 10.1001/jamaneurol.2013.5528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5528</ArticleId><ArticleId IdType="pmc">PMC3940333</ArticleId><ArticleId IdType="pubmed">24366103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K., Chan J., Macklin E.A., Levine-Weinberg M., Breen C., Bakshi R., Grasso D.L., Wills A.M., Jahandideh S., Taylor A.A., et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2018;5:1522&#x2013;1533. doi: 10.1002/acn3.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.671</ArticleId><ArticleId IdType="pmc">PMC6292193</ArticleId><ArticleId IdType="pubmed">30564619</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Mayo J.C., Tan D.X., Sainz R.M., Alatorre-Jimenez M., Qin L. Melatonin as an antioxidant: Under promises but over delivers. J. Pineal. Res. 2016;61:253&#x2013;278. doi: 10.1111/jpi.12360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12360</ArticleId><ArticleId IdType="pubmed">27500468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., Vijayalaxmi, Shepherd A.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998;253:614&#x2013;620. doi: 10.1006/bbrc.1998.9826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1998.9826</ArticleId><ArticleId IdType="pubmed">9918777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Feng Z., Zhang Q.Z., Zhang J.T. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 2006;27:129&#x2013;139. doi: 10.1111/j.1745-7254.2006.00267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2006.00267.x</ArticleId><ArticleId IdType="pubmed">16412260</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Bartels C., P&#xf6;lking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., H&#xfc;ther G., et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal. Res. 2006;41:313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnitskaya E.A., Muraleva N.A., Maksimova K.Y., Kiseleva E., Kolosova N.G., Stefanova N.A. Melatonin attenuates memory impairment, amyloid-&#x3b2; accumulation, and neurodegeneration in a rat model of sporadic Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2015;47:103&#x2013;116. doi: 10.3233/JAD-150161.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150161</ArticleId><ArticleId IdType="pubmed">26402759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.G., Woo Y.S., Park S.W., Seog D.H., Seo M.K., Bahk W.M. The neuroprotective effects of melatonin: Possible role in the pathophysiology of neuropsychiatric disease. Brain Sci. 2019;9:285. doi: 10.3390/brainsci9100285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci9100285</ArticleId><ArticleId IdType="pmc">PMC6826722</ArticleId><ArticleId IdType="pubmed">31640239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P. Melatonin: Clinical perspectives in neurodegeneration. Front. Endocrinol. 2019;10:480. doi: 10.3389/fendo.2019.00480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00480</ArticleId><ArticleId IdType="pmc">PMC6646522</ArticleId><ArticleId IdType="pubmed">31379746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandi-Perumal S.R., BaHammam A.S., Brown G.M., Spence D.W., Bharti V.K., Kaur C., Hardeland R., Cardinali D.P. Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes. Neurotox. Res. 2013;23:267&#x2013;300. doi: 10.1007/s12640-012-9337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-012-9337-4</ArticleId><ArticleId IdType="pubmed">22739839</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta. 2013;1830:4117&#x2013;4129. doi: 10.1016/j.bbagen.2013.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2013.04.016</ArticleId><ArticleId IdType="pubmed">23618697</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldini G., Altomare A., Baron G., Vistoli G., Carini M., Borsani L., Sergio F. N-Acetylcysteine as an antioxidant and disulphide breaking agent: The reasons why. Free Radic. Res. 2018;52:751&#x2013;762. doi: 10.1080/10715762.2018.1468564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715762.2018.1468564</ArticleId><ArticleId IdType="pubmed">29742938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiolo G., Bramanti P., Mazzon E. Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules. 2018;23:3305. doi: 10.3390/molecules23123305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23123305</ArticleId><ArticleId IdType="pmc">PMC6320789</ArticleId><ArticleId IdType="pubmed">30551603</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavarsad Shahripour R., Harrigan M.R., Alexandrov A.V. N-acetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4:108&#x2013;122. doi: 10.1002/brb3.208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.208</ArticleId><ArticleId IdType="pmc">PMC3967529</ArticleId><ArticleId IdType="pubmed">24683506</ArticleId></ArticleIdList></Reference><Reference><Citation>Remington R., Bechtel C., Larsen D., Samar A., Doshanjh L., Fishman P., Luo Y., Smyers K., Page R., Morrell C., et al. A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2015;45:395&#x2013;405. doi: 10.3233/JAD-142499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142499</ArticleId><ArticleId IdType="pubmed">25589719</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl W., Sies H. Antioxidant defense: Vitamins E and C and carotenoids. Diabetes. 1997;46:S14&#x2013;S18. doi: 10.2337/diab.46.2.S14.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.46.2.S14</ArticleId><ArticleId IdType="pubmed">9285493</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina S., Mart&#xed;nez M., Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic. Res. 2002;36:1179&#x2013;1184. doi: 10.1080/107157602100006445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/107157602100006445</ArticleId><ArticleId IdType="pubmed">12592670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kook S.Y., Lee K.M., Kim Y., Cha M.Y., Kang S., Baik S.H., Lee H., Park R., Mook-Jung I. High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice. Cell Death Dis. 2014;5:e1083. doi: 10.1038/cddis.2014.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.26</ArticleId><ArticleId IdType="pmc">PMC3944243</ArticleId><ArticleId IdType="pubmed">24577081</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit S., Fessel J.P., Harrison F.E. Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer&#x2019;s disease and a novel protective role for ascorbate. Free Radic. Biol. Med. 2017;112:515&#x2013;523. doi: 10.1016/j.freeradbiomed.2017.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.08.021</ArticleId><ArticleId IdType="pmc">PMC5623070</ArticleId><ArticleId IdType="pubmed">28863942</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraju T.R., Khaza&#x2019;ai H., Vidyadaran S., Abd Mutalib M.S., Vasudevan R. The neuroprotective effects of tocotrienol rich fraction and alpha tocopherol against glutamate injury in astrocytes. Bosn. J. Basic Med. Sci. 2014;14:195&#x2013;204. doi: 10.17305/bjbms.2014.4.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.17305/bjbms.2014.4.91</ArticleId><ArticleId IdType="pmc">PMC4333972</ArticleId><ArticleId IdType="pubmed">25428670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloesser A., Esatbeyoglu T., Piegholdt S., Dose J., Ikuta N., Okamoto H., Ishida Y., Terao K., Matsugo S., Rimbach G. Dietary tocotrienol/&#x3b3;-cyclodextrin complex increases mitochondrial membrane potential and ATP concentrations in the brains of aged mice. Oxid. Med. Cell Longev. 2015;2015:789710. doi: 10.1155/2015/789710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/789710</ArticleId><ArticleId IdType="pmc">PMC4537756</ArticleId><ArticleId IdType="pubmed">26301044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S., Huang X., Zhen J., Van Halm-Lutterodt N., Wang J., Zhou C., Yuan L. Dietary vitamin E status dictates oxidative stress outcomes by modulating effects of fish oil supplementation in Alzheimer disease model APP. Mol. Neurobiol. 2018;55:9204&#x2013;9219. doi: 10.1007/s12035-018-1060-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1060-6</ArticleId><ArticleId IdType="pubmed">29656360</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne D., McGuinness B., Woodside J.V., McKay G.J. Vitamin E and Alzheimer&#x2019;s disease: What do we know so far? Clin. Interv. Aging. 2019;14:1303&#x2013;1317. doi: 10.2147/CIA.S186760.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S186760</ArticleId><ArticleId IdType="pmc">PMC6645610</ArticleId><ArticleId IdType="pubmed">31409980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996;39:147&#x2013;157. doi: 10.1002/ana.410390203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390203</ArticleId><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiedor J., Burda K. Potential role of carotenoids as antioxidants in human health and disease. Nutrients. 2014;6:466&#x2013;488. doi: 10.3390/nu6020466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu6020466</ArticleId><ArticleId IdType="pmc">PMC3942711</ArticleId><ArticleId IdType="pubmed">24473231</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Amin M.M., Akhter S., Hasan A.T., Alam T., Nageeb Hasan S.M., Saifullah A.R., Shohel M. The antioxidant effect of astaxanthin is higher in young mice than aged: A region specific study on brain. Metab. Brain Dis. 2015;30:1237&#x2013;1246. doi: 10.1007/s11011-015-9699-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-015-9699-4</ArticleId><ArticleId IdType="pubmed">26116165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobos P., Bruna B., Cordova A., Barattini P., Gal&#xe1;z J.L., Adasme T., Hidalgo C., Mu&#xf1;oz P., Paula-Lima A. Astaxanthin protects primary hippocampal neurons against noxious effects of A&#x3b2;-oligomers. Neural Plast. 2016;2016:3456783. doi: 10.1155/2016/3456783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/3456783</ArticleId><ArticleId IdType="pmc">PMC4791503</ArticleId><ArticleId IdType="pubmed">27034843</ArticleId></ArticleIdList></Reference><Reference><Citation>Uittenbogaard M., Chiaramello A. Mitochondrial biogenesis: A therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr. Pharm. Des. 2014;20:5574&#x2013;5593. doi: 10.2174/1381612820666140305224906.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612820666140305224906</ArticleId><ArticleId IdType="pmc">PMC4823001</ArticleId><ArticleId IdType="pubmed">24606804</ArticleId></ArticleIdList></Reference><Reference><Citation>Eschbach J., von Einem B., M&#xfc;ller K., Bayer H., Scheffold A., Morrison B.E., Rudolph K.L., Thal D.R., Witting A., Weydt P., et al. Mutual exacerbation of peroxisome proliferator-activated receptor &#x3b3; coactivator 1&#x3b1; deregulation and &#x3b1;-synuclein oligomerization. Ann. Neurol. 2015;77:15&#x2013;32. doi: 10.1002/ana.24294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24294</ArticleId><ArticleId IdType="pmc">PMC4293280</ArticleId><ArticleId IdType="pubmed">25363075</ArticleId></ArticleIdList></Reference><Reference><Citation>Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658&#x2013;662. doi: 10.1038/nature03434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03434</ArticleId><ArticleId IdType="pubmed">15800627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet T., Berna P., Abitbol J.L., Pruss R.M. Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals. 2010;3:345&#x2013;368. doi: 10.3390/ph3020345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph3020345</ArticleId><ArticleId IdType="pmc">PMC4033913</ArticleId><ArticleId IdType="pubmed">27713255</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber J.J., Clemensson L.E., Schi&#xf6;th H.B., Nguyen H.P. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate. Biochem. Pharmacol. 2019;168:305&#x2013;318. doi: 10.1016/j.bcp.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.07.002</ArticleId><ArticleId IdType="pubmed">31283931</ArticleId></ArticleIdList></Reference><Reference><Citation>Demarin V., Podobnik S.S., Storga-Tomic D., Kay G. Treatment of Alzheimer&#x2019;s disease with stabilized oral nicotinamide adenine dinucleotide: A randomized, double-blind study. Drugs Exp. Clin. Res. 2004;30:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134388</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B.A., Pehar M., Sharma D.R., Beeson G., Beeson C.C., Vargas M.R. Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1) J. Biol. Chem. 2016;291:10836&#x2013;10846. doi: 10.1074/jbc.M115.698779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698779</ArticleId><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe C.R., Mochel F. Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. J. Inherit. Metab. Dis. 2006;29:332&#x2013;340. doi: 10.1007/s10545-006-0290-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10545-006-0290-3</ArticleId><ArticleId IdType="pubmed">16763896</ArticleId></ArticleIdList></Reference><Reference><Citation>Adanyeguh I.M., Rinaldi D., Henry P.G., Caillet S., Valabregue R., Durr A., Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015;84:490&#x2013;495. doi: 10.1212/WNL.0000000000001214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001214</ArticleId><ArticleId IdType="pmc">PMC4336068</ArticleId><ArticleId IdType="pubmed">25568297</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera T.W., Wong Y., Barkl-Luke M.E., Ngo S.T., Thomas N.K., McDonald T.S., Borges K. Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS ONE. 2016;11:e0161816. doi: 10.1371/journal.pone.0161816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161816</ArticleId><ArticleId IdType="pmc">PMC5001695</ArticleId><ArticleId IdType="pubmed">27564703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolaj I., Imindu Liyanage S., Weaver D.F. Phenylpropanoids and Alzheimer&#x2019;s disease: A potential therapeutic platform. Neurochem. Int. 2018;120:99&#x2013;111. doi: 10.1016/j.neuint.2018.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2018.08.001</ArticleId><ArticleId IdType="pubmed">30098379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bors W., Heller W., Michel C., Saran M. Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. Methods Enzymol. 1990;186:343&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">2172711</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskaug J., Carlsen H., Myhrstad M.C., Blomhoff R. Polyphenols and glutathione synthesis regulation. Am. J. Clin. Nutr. 2005;81:277S&#x2013;283S. doi: 10.1093/ajcn/81.1.277S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/81.1.277S</ArticleId><ArticleId IdType="pubmed">15640491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J.L., Wilhelmus M.M., de Vries H.E., Drukarch B., Hoozemans J.J., van Horssen J. Antioxidative defense mechanisms controlled by Nrf2: State-of-the-art and clinical perspectives in neurodegenerative diseases. Arch. Toxicol. 2014;88:1773&#x2013;1786. doi: 10.1007/s00204-014-1338-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-014-1338-z</ArticleId><ArticleId IdType="pubmed">25164826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorani M., Guidarelli A., Blasa M., Azzolini C., Candiracci M., Piatti E., Cantoni O. Mitochondria accumulate large amounts of quercetin: Prevention of mitochondrial damage and release upon oxidation of the extramitochondrial fraction of the flavonoid. J. Nutr. Biochem. 2010;21:397&#x2013;404. doi: 10.1016/j.jnutbio.2009.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2009.01.014</ArticleId><ArticleId IdType="pubmed">19278846</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.H., Kwon H., Kim K.S., Kim J., Kim M.H., Yu H.J., Kim M., Lee K.W., Do B.R., Jung H.K., et al. Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Toxicology. 2004;202:213&#x2013;225. doi: 10.1016/j.tox.2004.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2004.05.008</ArticleId><ArticleId IdType="pubmed">15337584</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., Luo T., Li S., Zhou Y., Shen X.Y., He F., Xu J., Wang H.Q. Quercetin protects against okadaic acid-induced injury via MAPK and PI3K/Akt/GSK3&#x3b2; signaling pathways in HT22 hippocampal neurons. PLoS ONE. 2016;11:e0152371. doi: 10.1371/journal.pone.0152371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152371</ArticleId><ArticleId IdType="pmc">PMC4822954</ArticleId><ArticleId IdType="pubmed">27050422</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D.S., Yu Y.C., Wu C.H., Lin J.Y. Protective effects of wogonin against Alzheimer&#x2019;s disease by inhibition of amyloidogenic pathway. Evid. Based Complement. Alternat. Med. 2017;2017:3545169. doi: 10.1155/2017/3545169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/3545169</ArticleId><ArticleId IdType="pmc">PMC5478820</ArticleId><ArticleId IdType="pubmed">28680449</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., del Valle J., Modol L., Martinez A., Granado-Serrano A.B., Ramirez-N&#xfa;&#xf1;ez O., Pall&#xe1;s M., Portero-Otin M., Osta R., Navarro X. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics. 2014;11:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996124</ArticleId><ArticleId IdType="pubmed">24414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa C., Hebron M., Huang X., Ahn J., Rissman R.A., Aisen P.S., Turner R.S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer&#x2019;s disease. J. Neuroinflammation. 2017;14:1. doi: 10.1186/s12974-016-0779-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0779-0</ArticleId><ArticleId IdType="pmc">PMC5234138</ArticleId><ArticleId IdType="pubmed">28086917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C.W., Grossman H., Neugroschl J., Parker S., Burden A., Luo X., Sano M. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer&#x2019;s disease: A pilot study. Alzheimers Dement. 2018;4:609&#x2013;616. doi: 10.1016/j.trci.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.09.009</ArticleId><ArticleId IdType="pmc">PMC6240843</ArticleId><ArticleId IdType="pubmed">30480082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Toninelli G., Maccarinelli G., Uberti D., Buerger E., Memo M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol. 2010;10:2. doi: 10.1186/1471-2210-10-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2210-10-2</ArticleId><ArticleId IdType="pmc">PMC2829550</ArticleId><ArticleId IdType="pubmed">20137065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 1998;71:295&#x2013;301. doi: 10.1046/j.1471-4159.1998.71010295.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.71010295.x</ArticleId><ArticleId IdType="pubmed">9648878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayeed I., Parvez S., Winkler-Stuck K., Seitz G., Trieu I., Wallesch C.W., Sch&#xf6;nfeld P., Siemen D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 2006;20:556&#x2013;558. doi: 10.1096/fj.05-4748fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4748fje</ArticleId><ArticleId IdType="pubmed">16407457</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin E.J., Nam Y., Lee J.W., Nguyen P.T., Yoo J.E., Tran T.V., Jeong J.H., Jang C.G., Oh Y.J., Youdim M.B.H., et al. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a selegiline analog, attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: Involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change. Mol. Neurobiol. 2016;53:6251&#x2013;6269. doi: 10.1007/s12035-015-9527-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9527-1</ArticleId><ArticleId IdType="pubmed">26563498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.Q., Qiu K., Liu H., He Q., Bai J.H., Lu W. Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin. Med. J. 2019;132:1467&#x2013;1477. doi: 10.1097/CM9.0000000000000289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000289</ArticleId><ArticleId IdType="pmc">PMC6629339</ArticleId><ArticleId IdType="pubmed">31205106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor S. Dl-3-n-butylphthalide and its emerging beneficial effects in neurology. Chin. Med. J. 2012;125:3360.</Citation><ArticleIdList><ArticleId IdType="pubmed">23126014</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong N., Huang J., Chen C., Zhao Y., Zhang Z., Jia M., Hou L., Yang H., Cao X., Liang Z., et al. Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson&#x2019;s disease. Neurobiol. Aging. 2012;33:1777&#x2013;1791. doi: 10.1016/j.neurobiolaging.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.03.007</ArticleId><ArticleId IdType="pubmed">21524431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Ye M., Xu W., Yu M., Liu X., Chen Y. DL-3-n-butylphthalide therapy for Parkinson&#x2019;s disease: A randomized controlled trial. Exp. Ther. Med. 2019;17:3800&#x2013;3806. doi: 10.3892/etm.2019.7397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.7397</ArticleId><ArticleId IdType="pmc">PMC6447885</ArticleId><ArticleId IdType="pubmed">30988766</ArticleId></ArticleIdList></Reference><Reference><Citation>Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525&#x2013;531. doi: 10.1053/jhep.2002.36088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2002.36088</ArticleId><ArticleId IdType="pubmed">12198643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman H.D., Gerhard G.S. Bile acids in neurodegenerative disorders. Front. Aging Neurosci. 2016;8:263. doi: 10.3389/fnagi.2016.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00263</ArticleId><ArticleId IdType="pmc">PMC5118426</ArticleId><ArticleId IdType="pubmed">27920719</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2002;99:10671&#x2013;10676. doi: 10.1073/pnas.162362299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162362299</ArticleId><ArticleId IdType="pmc">PMC125009</ArticleId><ArticleId IdType="pubmed">12149470</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Cunha C., Gomes C., Schmucki N., Barbosa M., Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 2015;51:864&#x2013;877. doi: 10.1007/s12035-014-8731-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8731-8</ArticleId><ArticleId IdType="pubmed">24848512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell S.M., Barnes K., Clemmens H., Al-Rafiah A.R., Al-Ofi E.A., Leech V., Bandmann O., Shaw P.J., Blackburn D.J., Ferraiuolo L., et al. Ursodeoxycholic acid improves mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial Alzheimer&#x2019;s disease. J. Mol. Biol. 2018;430:3942&#x2013;3953. doi: 10.1016/j.jmb.2018.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2018.08.019</ArticleId><ArticleId IdType="pmc">PMC6193139</ArticleId><ArticleId IdType="pubmed">30171839</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia A.E., Lalli S., Monsurr&#xf2; M.R., Sagnelli A., Taiello A.C., Reggiori B., La Bella V., Tedeschi G., Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:45&#x2013;52. doi: 10.1111/ene.12664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12664</ArticleId><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817734</ArticleId><ArticleId IdType="pubmed">31700226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth B., Karakaya M., Kye M.J., Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next. Annu. Rev. Genomics Hum. Genet. 2020;21 doi: 10.1146/annurev-genom-102319-103602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genom-102319-103602</ArticleId><ArticleId IdType="pubmed">32004094</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>